News

We are thrilled to announce the triumphant participation of our visionary Founder & CEO, Sharon Chen, at BiotechX US 2025! The event, held from September 16-17, 2025, in Philadelphia, PA, was a hub of innovation, bringing together global executives, speakers, sponsors, and startups in diagnostics, precision medicine, and digital transformation in pharmaceutical development and healthcare.

Sharon's presence was truly impactful, especially during her keynote presentation titled "How Leading Global Pharma Embraces AI to Automate Regulatory and Medical Documents with Quality Control". In this vital 15-minute presentation, she delved into how top pharmaceutical organizations are revolutionizing document creation by leveraging AI-driven solutions. Her speech showcased the implementation of AI to automate the drafting of high-quality clinical and regulatory content, including protocols, Clinical Study Reports (CSRs), and Investigator Brochures (IBs), while embedding robust quality control mechanisms throughout the workflow. Attendees gained invaluable insights into best practices for aligning AI tools with internal compliance standards, ensuring traceability, and driving efficiency across cross-functional teams, ultimately accelerating timelines and enhancing consistency, scalability, and collaboration in regulatory and medical writing operations.

The "AI in Clinical Trials" session (Track 204C) was met with enthusiastic reception. This dynamic session, which ran from 11:40 AM to 1:25 PM on September 16, featured insightful discussions and a compelling panel. We extend our sincere gratitude to Yael Gozin, Founder of Magrathea Health, and Afiya Perkins, Managing Director, Health & Life Sciences at Microsoft, for their invaluable contributions as speakers and panelists. Afiya skillfully hosted the panel discussion, where Yael and Sharon provided expert perspectives on key topics such as the proven business values delivered by AI systems, the top enterprise barriers to AI adoption, the requirements AI solutions must meet for regulatory documentation, and the vital change-management practices for sustained and scalable AI adoption in global enterprises. Their collective expertise truly illuminated the path forward for AI in life sciences!

A huge thank you to everyone who visited our booth, Number 903! It was a pleasure to connect with so many of you and discuss how AlphaLife Sciences is transforming life sciences R&D.

Missed us at BiotechX US 2025 or want to learn more? Our AuroraPrime solution is designed to transform document creation with AI automation, data management, seamless integration, regulatory compliance, and customizable modules. It's an advanced AI platform for medical content authoring, delivering agentic solutions that enhance the automated creation of regulatory documents across all phases of R&D. With AuroraPrime, industry leaders have seen remarkable results, including a 90% reduction in first draft time for Clinical Study Reports and Protocols, and a 95% reduction for Safety Narratives. Overall time savings can be as high as 50% for CSRs and Protocols, and 70% for Safety Narratives!

Curious to see how AuroraPrime can empower your enterprise to achieve transformative outcomes by streamlining document writing and generation? Connect with us today!

👉 Learn more about our AuroraPrime solution and get in touch here: https://alphalifesci.com/contact-us